Bei Akademie registrieren
RKDA, US0390143032

Arcadia Biosciences stock heads into Q3 report with estimates in focus

Published on 11/03/2026 at 03:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Arcadia Biosciences stock faces a November 5 earnings release before the US open. Investors are watching revenue and another expected loss.

What investors are watching next

  • Arcadia Biosciences is expected to report third-quarter results before the US market opens.
  • MarketBeat's outlook points to higher revenue but a sharply negative earnings result.
  • The company entered the report with a recent earnings miss still shaping expectations.
RKDA, US0390143032, Illustration mit AI erstellt.
RKDA, US0390143032, Illustration mit AI erstellt.

Arcadia Biosciences is expected to release its third-quarter 2026 results before the US market opens on Thursday, November 5. MarketBeat lists the announcement date as an estimate and says the timing could change.

Estimates set a demanding bar

MarketBeat's consensus calls for revenue of USD 2.40 million and a loss of USD 0.46 per share. The comparable quarter a year earlier produced revenue of USD 1.30 million and earnings of USD 0.62 per share, leaving investors to weigh expected sales growth against a sharply weaker earnings result.

The company last reported on August 13, 2026, when it posted a loss of USD 2.09 per share and missed the consensus estimate by USD 1.53, according to MarketBeat. Its recent record shows four consensus EPS beats in the last eight quarters.

Business remains tied to plant science

Arcadia Biosciences develops crops and plant-derived ingredients intended to support healthier food and wellness products. Its portfolio has included GoodWheat and GoodHemp, while its business combines agricultural research, product development, licensing and commercialization. The company is based in Davis, California, and operates in agricultural biotechnology and food ingredients; the available company materials do not establish a sufficiently specific named peer comparison.

The broader US equity market remains the relevant backdrop for the company ahead of the release. Follow current S&P 500 market reports.

More company information is available on the Arcadia Biosciences investor page. Read more news and analyses on Arcadia Biosciences stock.

Arcadia Biosciences at a glance

  • Company: Arcadia Biosciences, Inc.
  • ISIN: US0390143032
  • Ticker: RKDA
  • Primary market: Nasdaq
  • Next report: Third-quarter 2026 results, expected November 5, 2026, before the US market opens
Disclaimer...
en | US0390143032 | RKDA | boerse | 70448295 |